200,000 Shares in Tilray Inc (NASDAQ:TLRY) Bought by Brevan Howard Capital Management LP

Brevan Howard Capital Management LP purchased a new stake in shares of Tilray Inc (NASDAQ:TLRY) in the fourth quarter, Holdings Channel reports. The firm purchased 200,000 shares of the company’s stock, valued at approximately $266,000.

Other institutional investors have also added to or reduced their stakes in the company. Captrust Financial Advisors boosted its holdings in shares of Tilray by 535.5% during the fourth quarter. Captrust Financial Advisors now owns 115,825 shares of the company’s stock worth $154,000 after purchasing an additional 97,600 shares during the period. Raffles Associates LP purchased a new stake in Tilray in the fourth quarter worth $332,000. Schonfeld Strategic Advisors LLC boosted its holdings in Tilray by 68.0% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 35,121 shares of the company’s stock valued at $47,000 after acquiring an additional 14,221 shares in the last quarter. Lido Advisors LLC purchased a new position in Tilray during the 4th quarter valued at $28,000. Finally, The Manufacturers Life Insurance Company raised its holdings in Tilray by 9.9% in the 4th quarter. The Manufacturers Life Insurance Company now owns 786,874 shares of the company’s stock worth $1,042,000 after purchasing an additional 71,202 shares in the last quarter. Hedge funds and other institutional investors own 9.35% of the company’s stock.

Tilray Stock Performance

Shares of TLRY stock opened at $0.43 on Monday. The company has a current ratio of 2.54, a quick ratio of 1.58 and a debt-to-equity ratio of 0.10. The company’s fifty day moving average price is $0.56 and its 200-day moving average price is $1.00. The stock has a market cap of $429.77 million, a PE ratio of -1.42 and a beta of 1.95. Tilray Inc has a 12 month low of $0.41 and a 12 month high of $2.31.

Tilray (NASDAQ:TLRY) last posted its quarterly earnings data on Tuesday, April 8th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.06). Tilray had a negative return on equity of 4.40% and a negative net margin of 30.95%. The business had revenue of $185.78 million for the quarter, compared to the consensus estimate of $213.38 million. On average, equities analysts expect that Tilray Inc will post -0.2 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Roth Capital reaffirmed a “neutral” rating on shares of Tilray in a research note on Monday, April 14th. Canaccord Genuity Group lifted their price objective on Tilray from $2.00 to $3.00 and gave the company a “buy” rating in a research report on Monday, January 13th. Finally, Piper Sandler decreased their target price on Tilray from $2.00 to $1.00 and set a “neutral” rating for the company in a research report on Wednesday, April 9th.

About Tilray

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.